Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Investor Presentation (August 2025)
14 slides from Rhythm Biosciences's investor presentation, Aug 18, 2025
Slide 1: Placement Issue Investor Presentation
Placement Issue Investor Presentation 18 AUGUST 2025
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undert
Slide 3: About Rhythm Biosciences
About Rhythm Biosciences We are committed to Early detection of cancer gives individuals the best possible opportunity for favorable treatment outcomes. saving lives through the evaluation of cancer risk Addressing large under-served global markets worth >USD$50bn and heavily supported by public and
Slide 4: Corporate overview
Corporate overview CORPORATE SNAPSHOT SHARE PRICE CHART - ASX:RHY ASX Code RHY $2.00 Share Price (13 August 2025) $0.105 $1.50 Shares on Issue (14 August 2025) 284,081M Unlisted & Listed Options (14 August 2025) 53.4M $1.00 Market Capitalisation $29.83M $0.50 Cash in Bank (30 June 2025) $1.4M Top 20
Slide 5: Rhythm Bioscience: An attractive investment opportunity
Rhythm Bioscience: An attractive investment opportunity Overview Growth Reasons to Invest Rhythm’s mission is to 1. Multi-product portfolio. detect cancer earlier and Rhythm is solving an reduce the burden of important clinical and 2. Addressing a significant TAM. cancer. We are developing economic
Slide 6: Detecting cancer earlier and maintaining wellness
Detecting cancer earlier and maintaining wellness The power of the combination of the Rhythm capabilities and portfolio Y N E U R Risk Assessment Disease Screening O J MONITORING AND Determination Minimally-invasive detection MINIMAL RESIDUAL T RISK ASSESSMENT DISEASE DETECTION of risk profile. of d
Slide 7: Our portfolio accesses different biology using similar products
Our portfolio accesses different biology using similar products Rhythm products are engineered for affordable quality Risk Assessment Disease Screening Product Format Reagent kits/service Reagent kit/service Patient Sample Cheek swab Blood What we measure DNA variation and clinical history Specific
Slide 8: Rhythm is targeting a significant global market
Rhythm is targeting a significant global market A global market of >0.5bn individuals potentially served by the Rhythm product platform. Genomic Platform: geneTypeTM Proteomic Platform: ColoSTAT® & Lung Cancer Screening Unscreened high risk for CRC cancer investigating disease presence. Increasingly
Slide 9: Product Launches and upgrades
Product Launches and upgrades A diversified mix of development stages and underlying technologies will drive value 2nd Gen CRC ColoSTAT® Lung cancer geneTypeTM Symptomatic geneTypeTM New Product Release Q1 Q2 Q3 Q4 2028 Ordering portal geneTypeTM update geneTypeTM update geneTypeTM update Implementa
Slide 10: Our combined platforms supports a highly comprehensive approach to cancer diagnostics
Our combined platforms supports a highly comprehensive approach to cancer diagnostics The potential RHY product portfolio addresses a huge total available market. E Y R N U O J T MONITORING AND RISK MINIMAL RESIDUAL N ASSESSMENT DISEASE DETECTION E Risk Assessment • • • • • • • • • I T P A Surveilla
Slide 11: Upcoming value inflection points
Upcoming value inflection points PRODUCT ITEM DESCRIPTION COMPLETION DATE ColoSTAT® Final clinical validation Evaluation of final testing system Q3 CY 2025 geneTypeTM strategic geneTypeTM Establishment of key commercial partners Q3 CY 2025 partnerships geneTypeTM geneTypeTM menu expansion Expansion
Slide 12: Capital Raising Overview & Options Offered under Prospectus
Capital Raising Overview & Options Offered under Prospectus Key details of the Offer Options (subject to Shareholder Approval at AGM) Attaching Options offered under the Prospectus for every 1 share applied Placement • Placement to sophisticated, professional and institutional investors of a for and
Slide 13: Indicative Timetable of Placement & Use of Funds
Indicative Timetable of Placement & Use of Funds Important dates* Use of funds Maximum Target Raise Placement ColoSTAT® Commercialisation & Market Ready Record Date of Trading Halt, Thursday 14 Build book Opens August 2025 Complete the development and production of the $1.25m Up to $1.5m ColoSTAT® M
Slide 14: Thank you!
Thank you! david.atkins@rhythmbio.com www.rhythmbio.com
Rhythm Biosciences — Investor Presentation (August 2025) on 6ix